Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?
Clinical Oncology · 2026-06 · 54 · 104157
DOI: 10.1016/j.clon.2026.104157 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Oncology, 2026-06. Verfasst von K Luo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China. Electronic a…. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China. Electronic address: josephkay@foxmail.com.
- Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China.
Zitieren
APA
Luo, K., Liu, S., & Liu, Y. (2026). Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?. Clinical Oncology, 54, 104157. https://doi.org/10.1016/j.clon.2026.104157
Vancouver
Luo K, Liu S, Liu Y. Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?. Clinical Oncology. 2026;54:104157. doi:10.1016/j.clon.2026.104157
BibTeX
@article{Luo2026,
author = {Luo, K and Liu, S and Liu, Y},
title = {Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Where Are We Headed?},
journal = {Clinical Oncology},
year = {2026},
volume = {54},
pages = {104157},
doi = {10.1016/j.clon.2026.104157}
}
EUVIMED